Abstract
Neurology and psychiatry were once considered to be such closely related disciplines that one practitioner commonly treated patients suffering from illnesses of either type. This close relationship has waned, however, and neurologists and psychiatrists now maintain separate journals and professional organizations. Although this separation has advantages, new problems have been created. Nowhere are the problems more evident than in the field of neuropharmacology, where drugs used to treat neurological disease often affect psychiatric function and drugs used to treat psychiatric illness produce neurological symptoms. Behavioral disorders by neurologists and movement disorders by psychiatrists are increasingly reported in their own respective specialty journals. However, clinicians in one area often use vague or technically imprecise terminology when describing the other field. As a result, a psychiatrist reading a neurologist’s report of a behavior or a neurologist reading a psychiatrist’s report of an abnormal movement cannot easily understand the description in terms of classification and presumed pathophysiology or pathogenesis. In this chapter, we hope to contribute to a reciprocal educational effort directed toward ameliorating this problem. This chapter will discuss drug-induced abnormal movements associated with the administration of neuroleptic agents and their classification, description, and pharmacology.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ayd, F. J., Jr., 1961a, A survey of drug-induced extrapyramidal reactions, DAMA 175: 1054–1060.
Ayd, F. J., Jr., 1961b, Neuroleptics and extrapyramidal reactions in psychiatric patients, Rev. Can. Biol. 20: 451–459.
Barbeau, A., 1978, Phosphatidylcholine (Lecithin) in neuroleptic disorders, Neurology 28: 358.
Bartholini, G., Stadler, H., and Lloyd, K. G., 1973, Cholinergic—dopaminergic interactions in the extrapyramidal system, in: Progress in the Treatment of Parkinsonism ( D. B. Caine, ed.), pp. 233–241, Raven Press, New York.
Bleuler, E. P., 1951, Textbook of Psychiatry, Dover, New York.
Boston Collaborative Drug Surveillance Program, 1973, Drug induced extrapyramidal symptoms: A cooperative study, JAMA 224: 889–891.
Brodai, A., 1969, Pathways mediating supraspinal influences on the spinal cord, in: Neurological Anatomy, pp. 151–243, Oxford University Press, New York.
Burke, R. E., Fahn, S., Jankovic, J., Marsden, C. D., Lang, A. E., Gollomp, S., and Ilson, J., 1982, Tardive dystonia: Late onset and persistent dystonia caused by antipsychotic drugs, Neurology 32: 1335–1346.
Carpenter, M. D., 1976, Human Neuroanatomy, William & Wilkins, Baltimore.
Crane, G. E., 1968, Tardive dyskinesias in patients treated with major neuroleptics: A review of the literature, Am. J. Psychiatry. 123 (Feb. Suppl.): 40–48.
Crane, G. E., 1974, Factors pre-disposing to drug-induced neurological side effects, in: Advances in Biochemical Psychopharmacology, Vol. 9 ( I. S. Forrest, C. J. Carr, and E. Usdin, eds.), pp. 269–279, Raven Press, New York.
Davis, K. L., Berger, P. A., and Hollister, L. E., 1975, Choline for tardive dyskinesia, N. Engl. J. Med. 293: 152.
Davis, K. L., Hollister, L. E., Barchas, J. D., and Berger, P. A., 1976, Choline in tardive dyskinesia and Huntington’s disease, Life Sci. 19: 1507–1515.
Detre, T. P., and Jarecki, H. G., 1971, Modern Psychiatric Treatment, Lippincott, Philadelphia. Duvoisin, R. C., 1972, Reserpine for tardive dyskinesia, N. Engl. J. Med. 286: 611.
Fahn, S., 1983, Treatment of tardive dyskinesia: Use of dopamine depleting agents, Clin. Neuropharmacol. 6: 151–158.
Gardos, G., Cole, J. O., and Tarsy, D., 1978, Withdrawal syndromes associated with antipsychotic drugs, Am. J. Psychiatry 135: 1321–1324.
Goetz, D. G., and Klawans, H. L., 1984, Tardive dyskinesia, in: Movement Disorders (J. Jankovic, ed.), Neurol. Clin. 2: 605–614.
Jaspers, K., 1963, General Psychopathology, pp. 179–185, University of Chicago Press, Chicago.
Jus, K., Jus, A., and Gautier, J., 1974, Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome, Int. J. Clin. Pharmacol. 9: 138–145.
Jus, A., Pineau, R., Lanchance, R., Pelchat, G., Jus, K., Pires, P., and Villeneuve, R., 1976, Epidemiology of tardive dyskinesia. Part I, Dis. Nerv. Syst. 37: 210–214.
Kartzinel, R., and Chase, T. N., 1977, Pharmacology of dystonia, in: Clinical Neuropharmacology, Vol. 2 ( H. L. Klawans, ed.), pp. 43–54, Raven press, New York.
Klawans, H. L., Jr., 1968, The pharmacology of parkinsonism: A review, Dis. Nerv. Syst. 29: 805–816.
Klawans, H. L., 1973, The Pharmacology of Extrapyramidal Movement Disorders, Karger, Basel. Klawans, H. L., and Rubovits, R., 1972, Central cholingeric—anticholinergic antagonism in Huntington’s chorea, Neurology 22: 107–112.
Klawans, H. L., Bergen, D., and Bruyn, G. W., 1973, Prolonged drug induced parkinsonism, Confin. Neurol. 35: 368–377.
Klawans, H. L., Carvey, P., Nausieda, P. A., Goetz, C. G., and Weiner, W. J., 1980a, Effect of dose and type of neuroleptic in an animal model of tardive dyskinesia, Neurology 30: 302.
Klawans, H. L., Goetz, C. G., and Perlik, S., 1986, Tardive dyskinesia: Review and update, Am. J. Psychiatry 137: 900–908.
Korsgaard, S., 1976, Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia, Acta Psychiatr. Scand. 54: 17–24.
Kraepelin, E., 1919, Dementia Praecox and Paraphrenia, Livingstone, Edinburgh.
Marsden, C. D., Tarsy, D., and Baldessarini, R. J., 1975, Spontaneous and drug-induced movement disorders in psychiatric patients, in: Psychiatric Aspects of Neurologic Disease ( D. F. Benson and D. Blumer, eds.), pp. 14–32, Grune & Stratton, New York.
McDowell, F. H., Lee, J. E., and Sweet, R. D., 1978, Extrapyramidal disease, in: Clinical Neu-rology ( A. B. Baker and L. H. Baker, eds.), pp. 1–67, Harper & Row, Hagerstown, Maryland.
Rubovits, R., and Klawans, H. L., 1972, Implication of amphetamine induced stereotyped behavior as a model for tardive dyskinesias, Arch. Gen. Psychiatry 27: 502–507.
Selby, G., 1968, Parkinson’s disease, in: Handbook of Clinical Neurology, Diseases of the Basal Ganglia, Vol. 6 ( B. Vinken and G. W. Bruyn, eds.) pp. 173–211, Elsevier North Holland, Amsterdam.
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., and Greenberg, D., 1974, Drugs, neurotransmitters and schizophrenia: Phenothiazines, amphetamines, and enzymes synthesizing psychotomimetic drugs aid schizophrenia research, Science 184: 1243–1253.
Sovner, R., and Dimascio, A., 1977, The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia, Am. J. Psychiatry 134: 1301–1302.
Villeneuve, A., 1972, The rabbit syndrome: A peculiar extrapyramidal reaction, Can. Psychiatr. Assoc. J. 17(Suppl. 2):SS69–72.
Weiner, W. J., and Bergen, D., 1977, Prevention and management of the side effects of levodopa, in: Clinical Neuropharmacology, Vol. 2 ( H. L. Klawans, ed.), pp. 1–20, Raven Press, New York.
Yaryura-Tobias, J. A., Diamond, B., and Merlis, S., 1972, Psychiatric manifestations of levodopa, Can. Psychiatr. Assoc. J. 17:SS123–128.
Young, R. R., and Shahani, B. T., 1979, Pharmacology of tremor, in: Clinical Neuropharmacology, Vol. 4 ( H. L. Klawans, ed.), pp. 139–156, Raven Press, New York.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Publishing Corporation
About this chapter
Cite this chapter
Goetz, C.G., Klawans, H.L., Tanner, C.M. (1986). Movement Disorders Induced by Neuroleptic Drugs. In: Shah, N.S., Donald, A.G. (eds) Movement Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5038-5_17
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5038-5_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5040-8
Online ISBN: 978-1-4684-5038-5
eBook Packages: Springer Book Archive